These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39321199)

  • 1. TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma.
    Li Q; Zhang K; Yu Y; Yu Z; Xu J; Shen W; Zhang L; Qu A; Liang H
    PLoS One; 2024; 19(9):e0310889. PubMed ID: 39321199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
    Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
    Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.
    Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G
    Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
    Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
    Qi J; Chen SS; Chiorazzi N; Rader C
    Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
    Li B; Zhang X; Shi S; Zhao L; Zhang D; Qian W; Zheng L; Gao J; Wang H; Guo Y
    Cancer Res; 2010 Aug; 70(15):6293-302. PubMed ID: 20631068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
    Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
    Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
    Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
    Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.
    King BC; Hamblin AD; Savage PM; Douglas LR; Hansen TH; French RR; Johnson PW; Glennie MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1093-105. PubMed ID: 23604105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R; Weiner GJ
    J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells.
    Xu Y; Li S; Wang Y; Liu J; Mao X; Xing H; Tian Z; Tang K; Liao X; Rao Q; Xiong D; Wang M; Wang J
    Hum Gene Ther; 2019 Apr; 30(4):497-510. PubMed ID: 30381966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.
    Zhao L; Tong Q; Qian W; Li B; Zhang D; Fu T; Duan S; Zhang X; Zhao J; Dai J; Wang H; Hou S; Guo Y
    Blood; 2013 Dec; 122(26):4230-6. PubMed ID: 24178967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
    Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
    J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
    Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S
    Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.